Vetoquinol - Drontal Multi Aroma Meat | Dogs XL 8cpr

Name:  Drontal Multi Aroma Carne XL

Category:  Anthelmintics, combinations.

Active ingredients:  Each tablet contains: febantel 525 mg, pyrantel 175 mg (equivalent to 504 mg of pyrantel embonate), praziquantel 175 mg.

Excipients: Corn starch, lactose monohydrate, microcrystalline cellulose, Povidone K25, magnesium stearate, sodium lauryl sulphate, colloidal anhydrous silica, croscarmellose sodium, meat flavour.

Pharmaceutical form: Blister

Container: Dividable Tablets

Target species: Dogs.

Directions: Treatment of mixed nematode and tapeworm infestations of the following species. NEMATODES. Ascarids (adults and late immature forms): Toxocara canis, Toxascaris leonina. Hookworms (adults): Uncinaria stenocephala, Ancylostoma caninum. Whipworms (adults): Trichuris vulpis. CESTODES (adults and immature forms): Echinococcus granulosus, Echinococcus multilocularis, Dipylidium caninum, Taenia spp.

Contraindications: Do not use in case of hypersensitivity to the active substances or to any of the excipients. Do not use during the first and second third of pregnancy.

Undesirable effects: In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports) mild and transient digestive tract disorders (e.g. vomiting) may occur.

Use during pregnancy, lactation or lay: Teratogenic effects attributed to high doses of febantel, administered during the early stages of pregnancy, have been reported in rats, sheep and dogs. The safety of the product has not been studied during the first and second third of pregnancy. Do not use in pregnant bitches during the first and second third of pregnancy. A single treatment during the last third of pregnancy or during lactation has been shown to be safe.

Interaction with other medicinal products and other forms of interaction: The anthelmintic effects of this product and products containing piperazine may be antagonized when the two drugs are used together.

Dosage and administration route: For oral administration only. For the treatment of dogs: 1 tablet per 35 kg of body weight (15 mg febantel,14.4 mg pyrantel embonate and 5 mg praziquantel/kg body weight). B.W. 7-17.5 kg: 1/2 tablet. B.W. 17.5-35 kg: 1 tablet. B.W. 35-52.5 kg: 1 tablet + 1/2 tablet. B.W.: 52.5-70 kg: 2 tablets. For every additional 17.5 kg of body weight, administer an additional half tablet. Administration and duration of treatment: The tablets are flavoured and studies have shown that they are palatable and are taken up spontaneously by the majority (88%) of dogs tested. The tablets can be administered with or without food. It is not necessary to restrict access to a normal diet before or after treatment. The tablets should be given in a single administration. After opening the blister, the remaining halved tablets should be discarded immediately or returned to the opened blister until use. For the need and frequency of repeat treatment, a veterinarian should be contacted. Do not use in dogs weighing less than 7 kg.

Overdose (symptoms, emergency procedures, antidotes) if necessary: Fleas serve as intermediate hosts for a common type of tapeworm, Dipylidium caninum. Tapeworm infestation will recur if intermediate hosts, such as fleas, mice, etc., are not controlled. Resistance to a particular class of anthelmintics may develop in a parasite following frequent, repeated use of an anthelmintic of that class. To minimise the risk of re-infestation or re-infestation, faeces should be collected and disposed of properly for 24 hours after treatment. Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. In the interests of good hygiene, those administering the product directly to a dog or by adding it to the dog's food should wash their hands afterwards. Other precautions: As it contains praziquantel, The product is effective against Echinococcus spp. which are not present in all EU Member States, but are becoming more common in some. Echinococcosis represents a risk to humans. Since echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on treatment, follow-up and human safety must be obtained from the relevant competent authority. Overdose: 10 times the recommended doses of the product have been tolerated by dogs and puppies without signs of adverse reactions.

Withdrawal period:  Not applicable.

Storage:  This veterinary medicinal product does not require any special storage conditions.